Adaptimmune extends CFO Gavin Wood's departure to August 31, 2025

Adaptimmune Therapeutics PLC

Original termination date of May 31, 2025 changed to August 31, 2025 by reason of redundancy.
Severance includes 12 months base salary, discretionary pro-rata bonus for 2025, and healthcare benefits for 12 months.
Share options continue vesting until August 31, 2025; vested options exercisable for 12 months thereafter.
All other provisions of the original letter agreement and service agreement obligations survive unchanged.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gavin Wood

Chief Financial Officer

Adaptimmune Therapeutics PLC

Effective: 2025-08-31
Filed: April 14, 2025, 7:59 PM ET

Mr. Wood’s employment with Adaptimmune Limited will end on August 31, 2025 (the “Revised Termination Date”) by reason of redundancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin Wood departed as Chief Financial Officer at Adaptimmune Therapeutics PLC.

Action: departure
Role: Chief Financial Officer

Exact text from the filing

Mr. Wood’s employment with Adaptimmune Limited will end on August 31, 2025 (the “Revised Termination Date”) by reason of redundancy.

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-25-004768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.